D
HEM파마
376270KOSDAQ39.0 / 100
Reference Date: 2026-10-23
Financial Score12.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, Operating Profit is on a declining trend. Plunged 16.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
HEM Pharma is a global microbiome specialist company offering personalized healthcare services and LBP (Live Biotherapeutic Products) discovery platforms. Utilizing its proprietary PMAS technology, the company simulates microbiome environments to provide customized solutions and collaborates with global pharmaceutical firms and Amway, expanding into markets such as Japan and Vietnam.
Number of Employees
101people
Average Salary
55.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
-151.43Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
117.61Industry Average 100.002.0Point
Higher than industry avg (caution)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲84.0% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼34.1% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -82.9% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (2%, downtrend)
Current 28,250Won52-week high 94,00052-week low 26,500
1-month return0.0Point
1m -16.42% (strong drop)
Volume trend3.0Point
Volume flat
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0